Angiogenesis in Melanoma

This publication has 88 references indexed in Scilit:

• Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial
  Published by Elsevier ,2014
• Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
  BMC Medical Genetics, 2007
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
  British Journal of Cancer, 2006
• Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
  British Journal of Cancer, 2006
• Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing
  European Journal Of Cancer, 2006
• The emergence of integrins: a personal and historical perspective
  Matrix Biology, 2004
• Integrin signalling during tumour progression
  Nature Reviews Molecular Cell Biology, 2004
• Glycosylation profile of integrin α3β1 changes with melanoma progression
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2003
• Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
  European Journal Of Cancer, 2003
• Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours
  Expert Opinion on Biological Therapy, 2001